PDF(Pubmed)
Abstract：
UNASSIGNED: This was a prospective randomized controlled trial in 200 cases presented with endometrial cavity fluid at the day of oocyte retrieval at a private fertility center from 2013 to 2021. The cases were randomized at day of ovum pickup into 2 groups: Group 1 (control group) (n = 100): conventional management with follow-up and reassessment by transvaginal ultrasound on day 5. Group 2 (interventional group) (n = 100): aspiration of the fluid was done and cases were given diosmin 500 mg 3 times per day till reassessment at embryo transfer day. In both groups, we proceeded with fresh embryo transfer if no fluid is present on day 5 or freeze-all policy if persistent fluid was detected.
UNASSIGNED: Endometrial fluid on the 5th day was significantly higher in the control group (28.0%) than in the interventional group (6.0%) (P < 0.001). Regarding pregnancy rate, although being higher in the interventional group (54.3% vs 50.0%), the difference was not statistically significant (P = 0.5). It was found that the intervention was associated with risk reduction of endometrial fluid (OR = 0.168, 95% CI = 0.065-0.429, P < 0.001.
UNASSIGNED: Aspiration of endometrial cavity fluid with diosmin intake increased the likelihood of fresh embryo transfer and with a slightly better pregnancy rate compared to conservative management.Clinical trial number: NCT02158000, Date of registration: 6/6/2014, Date of initial enrollment (first patient recruiting): 1/11/2014, URL: https://clinicaltrials.gov/ct2/show/NCT02158000.
UNASSIGNED: Endometrial fluid on the 5th day was significantly higher in the control group (28.0%) than in the interventional group (6.0%) (P < 0.001). Regarding pregnancy rate, although being higher in the interventional group (54.3% vs 50.0%), the difference was not statistically significant (P = 0.5). It was found that the intervention was associated with risk reduction of endometrial fluid (OR = 0.168, 95% CI = 0.065-0.429, P < 0.001.
UNASSIGNED: Aspiration of endometrial cavity fluid with diosmin intake increased the likelihood of fresh embryo transfer and with a slightly better pregnancy rate compared to conservative management.Clinical trial number: NCT02158000, Date of registration: 6/6/2014, Date of initial enrollment (first patient recruiting): 1/11/2014, URL: https://clinicaltrials.gov/ct2/show/NCT02158000.
摘要：
■这是一项前瞻性随机对照试验，对2013年至2021年在私人生育中心取卵当天出现子宫内膜腔积液的200例病例进行了研究。这些病例在取卵当天随机分为2组：第1组（对照组）（n=100）：常规管理，并在第5天通过经阴道超声进行随访和重新评估。第2组（介入组）（n=100）：进行液体抽吸，病例每天3次给予地奥司明500mg，直至胚胎移植日重新评估。在这两组中,如果在第5天没有液体存在,我们将进行新鲜胚胎移植;如果检测到持续性液体,我们将进行全部冷冻策略.
■第5天，对照组子宫内膜液（28.0％）明显高于介入组（6.0％）（P<0.001）。关于怀孕率，虽然介入组较高(54.3%vs50.0%)，差异无统计学意义(P=0.5)。结果发现干预与子宫内膜液风险降低相关(OR=0.168,95%CI=0.065～0.429,P<0.001。
■吸入含地奥司明的子宫内膜腔液增加了新鲜胚胎移植的可能性，与保守治疗相比，妊娠率略高。临床试验编号：NCT02158000，注册日期：2014年6月6日，初始招募日期（首次招募患者）：2014年1月11日，URL：https://clinicaltrials.gov/ct2/show/NCT02158000。
■第5天，对照组子宫内膜液（28.0％）明显高于介入组（6.0％）（P<0.001）。关于怀孕率，虽然介入组较高(54.3%vs50.0%)，差异无统计学意义(P=0.5)。结果发现干预与子宫内膜液风险降低相关(OR=0.168,95%CI=0.065～0.429,P<0.001。
■吸入含地奥司明的子宫内膜腔液增加了新鲜胚胎移植的可能性，与保守治疗相比，妊娠率略高。临床试验编号：NCT02158000，注册日期：2014年6月6日，初始招募日期（首次招募患者）：2014年1月11日，URL：https://clinicaltrials.gov/ct2/show/NCT02158000。
